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SECOND-LINE CHEMOTHERAPY IN ADVANCED CANCER OF THE
PANCREAS: A MULTICENTER SURVEY OF THE GRUPPO ONCO-
LOGICO ITALIA MERIDONALE ON THE ACTIVITY AND SAFETY
OF THE FOLFIRI REGIMEN IN CLINICAL PRACTICE
C. Arcara a, E. Maiello b, Giuliani c, N. Borsellino d, V. Gebbia a, G.
Colucci a. a La Maddalena, University of Palermo, Italy. b IRCSS Cura
Sollievo della Sofferenza, San Giovanni Rotondo, Italy. c Istituto Tumori,
Bari, Italy. dOsp. Buccheri, LaFerla, Palermo, Italy.
Introduction: In daily clinical practice second-line chemother-
apy is frequently given to patients with advanced pancreatic can-
cer failing gemcitabine-based first-line chemotherapy without
solid scientific support.
Patients and methods: A retrospective survey was carried out
including 26 patients pretreated with gemcitabine in monoche-
motherapy or in combination with oxaliplatin. Patients received
standard FOLFIRI regimen biweekly until progression or unac-
ceptable toxicity. FOLFIRI regimen included irinotecan (150
mg/m2 on day 1), leucovorin (20 mg/m2 bolus) before 5-FU
(400 mg/m2 bolus) followed by 22-hour continuous infusion of
600 mg/m2 on days 1–2).
Results: Five partial responses (19%) and eight stabilizations
(31%) were recorded for a tumor growth control rate of 50%. The
median TTP was 4 months (range 2–7 months), and median over-
all survival was 6.5 months (range 3–9 months). A stabilization of
PS and a subjective improvement of cancer-related symptoms
was recorded in 15 patients (57%).
Conclusions: Data presented in this paper support the use of
FOLFIRI regimen in the second-line treatment of APC patients.
However, the use of second-line chemotherapy should be care-
fully proposed to patients with good PS or those who had a good
response to first-line therapy.
doi:10.1016/j.ejcsup.2008.06.037
GASTROINTESTINAL STROMAL TUMOURS: TWO CASE REPORTS
P. Camplese, G. Santarelli, A. Pardolesi, T. Iarussi, F. Mucilli, R.
Sacco. Department of Surgery, UO Clinica Chirurgica, Chieti University,
Italy.
Introduction: Gastrointestinal stromal tumours are rare and
characterised by slow growth and with late symptoms. Surgical
removal and the last pharmacological innovations are the only
possible and potentially curative treatments.
Methods: From 1999 to 2007 we observed 3 patients who
received surgical treatment for gastrointestinal stromal tumours
arising in two cases from the stomach and in one case from the
oesophagus. We report one case of a stomach GIST intraoperative
occasional finding, during laparotomy for a perforated diverticu-
litis, and one case of a distal oesophagus GIST causing mild dys-
phagia. The first patient underwent total gastrectomy with
lymphadenectomy and Hartmann’s operation and the second
patient underwent tumour excision with a laparotomic transhia-
tal approach followed by a Nissen fundoplicatio.
Results: No postoperative mortality or major postoperative
complications were observed. Patients are still alive and in good
health.
Conclusion: The cases we report reopen the question of this
pathology which, with further therapeutic innovations, shows a
rather favourable course but requires a diagnosis at early
stages. Moreover, the case of stomach GIST is particularly repre-
sentative for the tumour remarkable size, other symptoms lacking
which delayed diagnosis compared to other gastrointestinal
localizations.
doi:10.1016/j.ejcsup.2008.06.038
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Background: Advanced hepatocellular carcinoma (HCC) not
amenable to local therapies has limited chances of cure and has
a poor prognosis. Sorafenib is a multikinase inhibitor with proven
activity in advanced HCC. Octreotide is already used in this set-
ting with conflicting but usually interesting results.
Methods: An original schedule with sorafenib and long-acting
octreotide is currently tested in advanced HCC enrolled from dif-
ferent institutions. Sorafenib is administered at a dosage of
400 mg/daily for 28 d with a following week of rest. Ten days after
starting sorafenib, long acting octreotide is administered at a dose
of 40 mg with monthly scheduled administrations. Objectives of
this study are the evaluation of activity and potential toxicity of
the treatment. Tumor response is assessed bimontly.
Results:At the date of 28 April 2008, 57 patientswere considered
for study entry and 42 were enrolled (sex: 33M/9F; age range: 57–80
years; HCV: 26 patients, HBV: 10 patients, HCV + HBV: 1 patient;
unknown etiology: 5 patients; childA/B: 31/11). Patients naı¨ve from
other therapieswere 19, whilst all the otherswere previously trea-
tedwith local and/or systemic treatments. Threepatientswere not
evaluable because of premature treatment stopping caused by
diarrhoea grade 3. Twenty-four patients were evaluated until
now. Among 12 patients evaluable after 2 months of therapy, we
registered 1 minimal response, 3 stable disease and 8 disease pro-
gression. Among 8 patients evaluable after 4 months, we reported
5 stable disease and 3 disease progression. Among 4 patients
evaluable after 6 months, we reported 1 minimal response and 3
stable disease. Treatment was generally well tolerated apart from
haemorrhoidal bleeding (2 patients), skin toxicity grade 2 and
grade 3 in 2 patients, respectively, hypertension in 3 patients.
Conclusions: The association of sorafenib and long acting octre-
otide appears feasible in advanced hepatocellular carcinomas not
susceptible of local therapies. Longer follow-up of this study is
needed to evaluate clinical activity of this schedule.
doi:10.1016/j.ejcsup.2008.06.039
BI-WEEKLY ADMINISTRATION OF CAPECITABINE + OXALIPLA-
TIN (XELOX-2) IN FIRST LINE TREATMENT OF ADVANCED
COLORECTAL CANCER (ACRC): PRELIMINARY RESULTS
M. Di Bisceglie a, G. Di Maggio a, F. Giuliani b, V. Lorusso c, S.
Cinieri d, G. Colucci b, E. Maiello a. aOncology Unit, IRCCS Casa
Sollievo della Sofferenza, S. Giovanni Rotondo, Italy. bMedical and
Experimental Oncology Unit, IRCCS Oncology Istitute, Bari, Italy.
cOncology Unit, V. Fazzi Hospital, Lecce, Italy. dOncology Unit, Perrino
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Background: FOLFOX regimen represents a standard first
line therapy for ACRC. Recent studies observed that tri-weekly
XELOX administration is characterised by effectiveness and toler-
ance similar to FOLFOX 4 infusional schedule. This phase II mul-
ticenter study of the Gruppo Oncologcio dell’Italia Meridionale
(GOIM) started to evaluate the activity and the toxicity of bi-
weekly administration of capecitabine + oxaliplatin in ACRC
patients.
Materials and methods: Thirty-two advanced colorectal cancer
pts with measurable disease, ECOG PS 6 2, age 18–75 years (yrs)
were enrolled. The schedule of treatment was as follows: oxalipl-
atin at 100 mg/mq i.v. on day 1 and capecitabine at 2000 mg/mq
p.o. in a two daily administration from days 1 to 7, every 2 weeks.
The recist and NCI criteria were employed to determine the activ-
ity and the toxicity of this combination, respectively.
Results: At present, 32 patients have been enrolled and up to
now 29 of them are evaluable for activity and toxicity. The main
characteristics were: sex (M/F) 23/9, median age 70 yrs (range
54–75), median PS 0, main sites of disease: liver 26 (81%),
lymph-nodes 9 (28%) and lung 4 (12%). One CR (3%) and 12 PR
(42%), 8 SD (27%) and 8 PD (27%) were observed. The main toxicity
rate (G1–2 versus G3–4) were: thrombocytopenia 44/6, anaemia
41/0, nausea/vomiting 28/0, diarrhoea 22/0, neurotoxicity 50/0
and asthenia 16/3.
Conclusions: These preliminary data show that the bi-weekly
administration of capecitabine + oxaliplatin is active and well tol-
erated by ACRC patients. This study is still ongoing.
doi:10.1016/j.ejcsup.2008.06.040
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Background: Irinotecan (Cpt-11) plus fluorouracil (Fu) modu-
lated by folinic acid (Fa) (folfiri regimen) is one of the standard
first-line treatment in advanced colorectal cancer (ACC). The oral
fluoropyrimidine xeloda (Xel) is equivalent in terms of efficacy
and demonstrated a better safety profile than bolus Fu–Fa.
Besides Xel can replace Fu continuous infusion. Also the combi-
nation of Cpt-11 plus Xel (xeliri regimen) demonstrated to be
active as a first-line treatment in ACC patients. So the GOIM
started a randomised multicenter phase II trial aiming to com-
pare the activity and safety of folfiri and xeliri in this setting.
Methods: Untreated patients with histologically confirmed
diagnosis of colorectal cancer entered into the trial if they satis-
fied the following inclusion criteria: presence of measurable dis-
ease (recist criteria), age > 18 years, performance status < 2 (Ecog
scale), adequate bone marrow reserve and renal and hepatic
function, informed written consent. The enrolled patients were
randomised 1:2 to receive arm A: Cpt-11 at 180 mg/m2 on day 1,
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